BLZ-100

DRUG5 trials

Sponsors

Blaze Bioscience Australia Pty Ltd, Blaze Bioscience Inc.

Conditions

Central Nervous System TumorsGliomaSarcoma, Soft TissueSkin NeoplasmsTumors, Breast

Phase 1

Safety Study of a Fluorescent Marker to Visualize Cancer Cells

CompletedNCT02097875

Blaze Bioscience Australia Pty LtdSkin Neoplasms

Start: 2013-12-31End: 2015-03-31Updated: 2015-04-21

Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery

CompletedNCT02234297

Blaze Bioscience Inc.Glioma

Start: 2014-10-31End: 2016-03-31Updated: 2016-04-06

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

CompletedNCT02462629

Blaze Bioscience Inc.Central Nervous System Tumors

Start: 2015-06-30End: 2018-08-31Updated: 2023-02-21

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

WithdrawnNCT02464332

Blaze Bioscience Inc.Sarcoma, Soft Tissue

Start: 2015-09-30End: 2016-05-31Updated: 2016-05-26

Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery

CompletedNCT02496065

Blaze Bioscience Inc.Tumors, Breast

Start: 2015-07-31End: 2017-01-31Updated: 2017-07-13

Related Papers

A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

2021-08-0423 citations

Tozuleristide pharmacokinetics from phase 1 studies in adult and pediatric subjects with central nervous system tumors undergoing surgery.

Journal of Clinical Oncology2018-05-20

Phase 1 dose escalation and expansion safety study of BLZ-100 in pediatric subjects with primary central nervous system tumors.

Journal of Clinical Oncology2016-05-203 citations

Phase 1 dose escalation and expansion safety study of BLZ-100 in subjects with skin cancer.

Journal of Clinical Oncology2015-05-201 citations